OssDsign - Analyst - ABG

Positive sales update for Q4
Oct-Nov sales of 25.2m (ABGSCe Q4 SEK 24)
Implied upside of 13% to our FY '23e sales estimates


Trading update after strong start to Q4

OssDsign is out with a positive trading update for Q4, with sales for October-November of SEK 25.2m, above market expectations for Q4 (ABGSCe SEK 24m, FactSet consensus SEK 23m). The strong sales performance is due to continued strong performance of the orthobiologics business and some extraordinary large orders from large hospitals, according to management. For the months of October-November, OssDisgn has recorded sales of SEK 18.8m for Catalyst and SEK 6.4m for its Cranial business, implying both products are doing better than we had expected as we had Catalyst/Orthobiologics sales in Q4 of SEK 21m and Cranial/CMF sales of 3.0m for Q4.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossdsign/Equity-research/2023/12/ossdsign---analyst/